
Background/Objectives: Human papillomavirus (HPV) is the most common sexually transmitted viral infection worldwide, with an estimated 630 million people currently infected, and poses significant health risks for men. While many will naturally clear the infection within a couple of years, persistent cancerous HPV strains are linked to several oncological diseases. The aim is to synthesize existing research on HPV in men to better understand its prevalence, risk factors, associated health outcomes, transmission dynamics, diagnostics, and vaccination strategies. Methods: A non-systematic narrative review was conducted, utilizing relevant studies published between 2010 and 2025 identified using multiple databases (Web of Science, PubMed, Scopus, and Google Scholar) and official health/vaccine websites. Results: Approximately one-third of men globally carry genital HPV, and approximately one-fifth carry one or more high-risk HPV types. Prevalence peaks in younger men but remains high throughout all ages. Key risk factors include sexual behavior, circumcision status, condom use, HIV, smoking, lower education, and vaccination status. More than 80% of infections are asymptomatic, and many men remain unaware due to lack of recommended screening. Emerging strategies focus on high-risk groups, using anal Pap smears and HPV DNA testing. Vaccination in males shows high efficacy, especially when administered before exposure, supporting expanded vaccination programs for all genders. However, global HPV vaccination coverage in men remains suboptimal. Strategies to improve uptake include provider recommendations, education, tailored campaigns, school programs, reminder systems, cost reduction, catch-up vaccination, and open communication. Conclusions: Expanding male-targeted prevention is critical to reducing the global burden of HPV-related diseases.
Background/Objectives: Sexually transmitted infections (STIs) continue to pose a global public health problem, exacerbated by barriers to access, stigma and the limitations of traditional screening models. Artificial intelligence (AI) has emerged as a tool with the potential to enhance early detection, risk stratification and personalised counselling. This article critically analyses the current role of AI in STI prevention (encompassing primary and secondary prevention, including early detection), identifying validated applications, limitations and ethical implications. Methods: A narrative review was conducted of the literature published between 2020 and 2026, using biomedical databases, with a focus on original studies, systematic reviews and documents from leading organisations on the applications of machine learning, computer vision and conversational agents in the prevention, diagnosis and surveillance of STIs, including HIV. Results: Machine learning algorithms applied to clinical and behavioural data stratify the individual risk of STIs with satisfactory performance, supporting the recommendation for pre-exposure prophylaxis. Computer vision systems for the early detection of STIs identify skin and genital lesions with reasonable accuracy, although generalisation to diverse populations remains limited. Chatbots have proven to be acceptable and effective in promoting HIV testing and adherence to PrEP, particularly among key populations. Challenges remain regarding algorithmic bias, privacy and the lack of established regulatory frameworks. Conclusions: AI is a promising complementary tool, rather than a substitute for conventional STI prevention strategies, and its implementation must be accompanied by rigorous clinical validation, human oversight and a deliberate focus on health equity.
Infectious diseases remain a major global public health concern, disproportionately causing morbidity and mortality in low- and middle-income countries. Sexually Transmitted Infections (STIs) heavily affect sexually active populations. Sex workers, encompassing female sex workers (FSWs), male sex workers (MSWs), and transgender/gender-diverse individuals, face heightened vulnerabilities due to occupational exposures, structural barriers, stigma, and criminalization. While substantial focus has historically centered on HIV, non-HIV STIs such as Neisseria gonorrhoeae, Chlamydia trachomatis, Treponema pallidum, and viral hepatitis present significant co-morbidity. Crucially, drug resistance across these pathogens presents distinct biological and epidemiological challenges: bacterial antimicrobial resistance (AMR) in N. gonorrhoeae and C. trachomatis, antiretroviral (ARV) resistance in HIV, and direct-acting antiviral (DAA) resistance in hepatitis B and C. This perspective article synthesizes the current epidemiological landscape, critiques the reliance on syndromic management over molecular diagnostics (e.g., NAATs, point-of-care, and genomic surveillance), highlights diagnostic stewardship, and outlines priority public health strategies aligned with the WHO 2022–2030 Global Health Sector Strategies.
Sexually transmitted infections (STIs) remain a public health challenge, with rising incidence rates and significant loss to follow-up in traditional testing models. Point-of-care (POC) testing promises same-day diagnosis and treatment, potentially transforming STI management. We conducted a narrative review with perspective elements of commercially available POC and near-POC tests for STIs, identifying tests through regulatory and product-specific sources including the Food and Drug Administration (FDA), World Health Organization (WHO) prequalification list, Australia’s Therapeutic Goods Administration (TGA), China’s National Medical Products Administration (NMPA), publicly available European regulatory and manufacturer sources for CE-marked in vitro diagnostic devices under the EU In Vitro Diagnostic Regulation framework, and the published literature. Several nucleic acid amplification test (NAAT)-based platforms now deliver results rapidly with excellent sensitivity and specificity for common bacterial and protozoal STIs, including Chlamydia trachomatis, Neisseria gonorrhoeae, and Trichomonas vaginalis. For viral STIs, POC testing is most mature for human immunodeficiency virus (HIV), with numerous approved rapid antibody tests, although viral load and resistance testing remain laboratory-based. Most NAAT platforms require dedicated instruments, specialized training, and significant infrastructure. At-home testing options are emerging but face challenges with sensitivity, public health surveillance, and regulatory oversight. In conclusion, POC testing for STIs is advancing but not yet fully realized, and true POC tests (those usable at the bedside without laboratory support) remain limited. While rapid NAAT platforms represent significant progress over traditional laboratory-based testing, barriers to true POC implementation persist. Future developments in antimicrobial resistance detection, multiplex testing, instrument-free platforms, and integration of at-home testing with public health surveillance will be critical to achieving broader STI testing and control.
Human Papillomavirus (HPV) is a highly prevalent sexually transmitted infection associated with malignancies of the cervix, vulva, and vagina. While prophylactic vaccination with Gardasil®9 is FDA-approved through age 45, no clinical trials have evaluated its use in older adults who remain sexually active and at risk for HPV-related cancers. We describe the case of a woman who presented with recurrent high-risk HPV and received the three-dose Gardasil®9 series off-label at the age of 67. Following vaccination, her cervical cytology was negative for HPV and subsequent colposcopy did not demonstrate any evidence of intraepithelial lesion or malignancy. As this is a single case report, this temporal association cannot establish that vaccination caused viral clearance. Nonetheless, this case raises important questions regarding age-based HPV vaccination limits. Immunosenescence in older populations may impair viral clearance and could increase cumulative risk of progression from dysplasia to malignancy. Vaccination may therefore serve both prophylactic and potentially therapeutic roles; however, this must be evaluated in further controlled studies. This case highlights the need for further research into HPV vaccination in patients over the age of 45 years with or without history of HPV infection.